Donepezil reduces the time caregivers spend providing care: Results of a one-year, double-blind randomized trial in patients with mild to moderate Alzheimer's disease.

被引：0
|
作者：
Mastey, V
Wimo, A
Winblad, B
Haglund, A
Jacobson, L
Miceli, R
Zhang, R
Subbiah, P
机构：
[1] Pfizer Inc, Pfizer Pharmaceut Grp, New York, NY USA
[2] Umea Univ, Dept Family Med, Umea, Sweden
[3] Karolinska Inst, Huddinge, Sweden
[4] Pfizer AB, Taby, Sweden
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2001年 / 49卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
P16
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [1] An economic evaluation of donepezil in mild to moderate Alzheimer's disease: Results of a one-year, double-blind, randomized trial.
    Mastey, V
    Wimo, A
    Winblad, B
    Haglund, A
    Jacobson, L
    Miceli, R
    Zhang, R
    Subbiah, P
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (04) : S131 - S131
  • [2] An economic evaluation of donepezil in mild to moderate Alzheimer's disease: Results of a 1-year, double-blind, randomized trial
    Wimo, A
    Winblad, B
    Engedal, K
    Soininen, H
    Verhey, F
    Waldemar, G
    Wetterholm, AL
    Mastey, V
    Haglund, A
    Zhang, R
    Miceli, R
    Chin, W
    Subbiah, P
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2003, 15 (01) : 44 - 54
  • [3] An economic evaluation of donepezil in mild to moderate Alzheimer's disease: Results of a 1-year, double-blind, randomized trial (vol 15, pg 44, 2003)
    Wimo
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2003, 16 (02) : 102 - 102
  • [4] Treatment with Cerebrolysin, donepezil and a combination therapy in mild to moderate Alzheimer's disease: a double-blind clinical trial
    Alvarez, A.
    Sampedro, C.
    Couceiro, V.
    Cacabelos, R.
    Garcia-Fantini, M.
    Aleixandre, M.
    Linares, C.
    Granizo, E.
    Doppler, E.
    Novak, P.
    Moessler, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 342 - 342
  • [5] Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers - A double-blind, head-to-head, randomized pilot study
    Ancoli-Israel, S
    Amatniek, J
    Ascher, S
    Sadik, K
    Ramaswamy, K
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2005, 19 (04): : 240 - 245
  • [6] Saffron reduces some inflammation and oxidative stress markers in donepezil-treated mild-to-moderate Alzheimer's Disease patients: A randomized double-blind placebo-control trial
    Marzabadi, Leila Rasi
    Fazljou, Seyyed Mohammad Bagher
    Araj-Khodaei, Mostafa
    Sadigh-Eteghad, Saeed
    Naseri, Amirreza
    Talebi, Mahnaz
    JOURNAL OF HERBAL MEDICINE, 2022, 33
  • [7] Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial with Magnetic Resonance Spectroscopy
    Modrego, Pedro J.
    Fayed, Nicolas
    Errea, Jose M.
    Rios, Consuelo
    Pina, Miguel A.
    Sarasa, Manuel
    NEUROLOGY, 2009, 72 (11) : A298 - A298
  • [8] Saffron reduces some inflammation and oxidative stress markers in donepezil-treated mild-to-moderate Alzheimer?s Disease patients: A randomized double-blind placebo-control trial
    Marzabadi, Leila Rasi
    Fazljou, Seyyed Mohammad Bagher
    Araj-Khodaei, Mostafa
    Sadigh-Eteghad, Saeed
    Naseri, Amirreza
    Talebi, Mahnaz
    JOURNAL OF HERBAL MEDICINE, 2022, 34
  • [9] Galantamine reduces time spent by caregivers in providing assistance for patients with Alzheimer's disease.
    Kaufer, DI
    Sadik, K
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2002, 50 (04) : S25 - S25
  • [10] Donepezil benefits patients with either mild or moderate Alzheimer's disease over one year
    Waldemar, G
    Winblad, B
    Engedal, K
    Soininen, HS
    Verhey, FRJ
    Wimo, A
    Wetterholm, AL
    Zhang, R
    Haglund, AÅ
    Subbiah, P
    NEUROLOGY, 2000, 54 (07) : A470 - A470
12345